Aortic arch operations, necessary for treating aortic aneurysms and dissections, are high-risk procedures with significant morbidity and mortality rates. Current surgical techniques often involve deep hypothermic circulatory arrest, a method introduced in 1952 that carries substantial physiological risks for the patient. The complexity and risk associated with these procedures can lead to hesitancy among both patients and surgeons, highlighting the need for safer and more effective solutions.

Octin Health is developing the Elika Device, a surgical solution designed to enable surgeons to perform aortic arch operations without the high physiological price of deep hypothermic circulatory arrest. The device aims to reduce the risks associated with current operative techniques, leading to safer procedures and improved patient outcomes. By addressing the limitations of existing methods, Octin Health seeks to transform aortic arch surgery, making it easier and more affordable for hospitals while improving patient survival rates and long-term health. The Elika Device is currently in the formal development stage and is not yet FDA cleared.

Designed to eliminate the need for deep hypothermic circulatory arrest during aortic arch operations.

Aims to reduce operative mortality and morbidity associated with aortic aneurysm and dissection surgeries.

Intended to simplify the surgical procedure, making it more accessible for hospitals and surgeons.

Focused on improving patient outcomes, including survival rates and long-term health.

The primary target audience includes cardiovascular surgeons specializing in aortic arch operations, as well as hospitals and medical centers that perform these complex procedures.